Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Neal Jain

Allergy & Immunology Gilbert, AZ Medical Doctor

NPI 1356390512 CMS profile 15741

4915 E Baseline Rd, Suite 112, Gilbert, AZ 85234

Open in the dashboard

General payments

$387,625

536 records reported · program years 2019–2024

Research payments

$17,744

Paid to them · 32 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,043,843 paid to institutions, not to them · program years 2019–2025

Through program year 2024, Neal Jain of Gilbert, AZ is reported in the CMS Open Payments database as having received $387,625 across 536 general payments and $17,744 in research payments paid to them. Separately, studies naming them as principal investigator received $1,043,843 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $49 1
2023 General $2,300 4
2022 General $66,032 110
2022 Research $8,366 19
2021 General $96,848 124
2021 Research $4,000 8
2020 General $64,294 74
2020 Research $5,378 5
2019 General $158,102 223

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Neal Jain
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Neal Jain were reported at $0. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Neal Jain Allergy & Immunology median Middle half National median
2019 $158,102 $594 $163–$1,512 $163
2020 $64,294 $426 $106–$1,233 $114
2021 $96,848 $638 $157–$1,708 $132
2022 $66,032 $790 $205–$1,961 $149
2023 $2,300 $852 $220–$2,147 $160
2024 $49 $865 $203–$2,267 $164
2025 $0 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Regeneron Healthcare Solutions, Inc. $129,565 155 payments
  2. AstraZeneca Pharmaceuticals LP $95,590 125 payments
  3. Genzyme Corporation $79,583 72 payments
  4. OptiNose US, Inc. $20,458 45 payments
  5. Novartis Pharmaceuticals Corporation $12,304 20 payments
  6. Circassia Pharmaceuticals Inc $11,280 9 payments
  7. Regeneron Pharmaceuticals, Inc. $10,106 9 payments
  8. Pfizer Inc. $8,051 18 payments
  9. Amgen Inc. $8,050 16 payments
  10. AstraZeneca AB $3,583 2 payments
  11. Other $9,055 65 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $184,576 108 payments
  2. Consulting Fee $173,408 87 payments
  3. Travel and Lodging $17,210 72 payments
  4. Food and Beverage $9,206 263 payments
  5. Honoraria $3,093 3 payments
  6. Education $134 3 payments
Products named General payments · program years 2019–2024
  1. DUPIXENT Inflammation And Immunology $138,196 162 payments
  2. DUPIXENT Immunology $45,095 33 payments
  3. DUPIXENT Immunology $37,482 46 payments
  4. FASENRA $32,205 49 payments
  5. TEZSPIRE Respiratory $26,326 18 payments
  6. Xhance $20,458 45 payments
  7. NIOX VERO $11,167 7 payments
  8. XOLAIR $8,467 13 payments
  9. TEZSPIRE Inflammation $5,716 10 payments
  10. QGE031 $3,270 1 payment
  11. Other $8,566 112 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Genzyme Corporation $10,500 26 payments
  2. Regeneron Pharmaceuticals, Inc. $4,066 3 payments
  3. Sanofi-Aventis U.S. LLC $1,603 2 payments
  4. AbbVie, Inc. $1,575 1 payment

Records

568 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record